

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
20 March 2025 (20.03.2025)



(10) International Publication Number
WO 2025/057134 A2

(51) International Patent Classification:

C07D 471/04 (2006.01) A61P 3/10 (2006.01)
A61P 3/04 (2006.01) A61P 9/10 (2006.01)

(21) International Application Number:

PCT/IB2024/058942

(22) International Filing Date:

13 September 2024 (13.09.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

202311189557.X	14 September 2023 (14.09.2023)	CN
63/538,892	18 September 2023 (18.09.2023)	US
202311371725.7	23 October 2023 (23.10.2023)	CN
63/545,615	25 October 2023 (25.10.2023)	US
202311582240.2	24 November 2023 (24.11.2023)	CN
63/603,854	29 November 2023 (29.11.2023)	US
202311686034.6	08 December 2023 (08.12.2023)	CN
202410142451.2	31 January 2024 (31.01.2024)	CN
202410202078.5	22 February 2024 (22.02.2024)	CN
202410398964.X	02 April 2024 (02.04.2024)	CN
202410584679.7	11 May 2024 (11.05.2024)	CN
202410963587.X	17 July 2024 (17.07.2024)	CN
63/673,453	19 July 2024 (19.07.2024)	US
202411237048.4	04 September 2024 (04.09.2024)	CN

(71) Applicant: **ASCLETIS PHARMA (CHINA) CO., LIMITED** [CN/CN]; Room 1903, 19/F, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong, 999077 (CN).

(72) Inventors: **LIANG, Bin**; Room 1903, 19/F, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong, 999077 (CN). **WU, Jinzi Jason**; Room 1903, 19/F, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong, 999077 (CN). **YANG, Bailing**; Room 1903, 19/F, Lee Gar-

den One, 33 Hysan Avenue, Causeway Bay, Hong Kong, 999077 (CN).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report (Rule 48.2(g))

(54) Title: GLP-1R AGONIST AND THERAPEUTIC METHOD THEREOF



(I)

(57) Abstract: The present disclosure describes GLP-1R modulating compounds that are useful for treating GLP-1R-mediated diseases or conditions, Formula (I).

WO 2025/057134 A2